Next Article in Journal
What Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis?
Next Article in Special Issue
Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway
Previous Article in Journal
Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression
Previous Article in Special Issue
A Radiomic-Based Machine Learning Model Predicts Endometrial Cancer Recurrence Using Preoperative CT Radiomic Features: A Pilot Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 5
10.3390/cancers16050965
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence

Cancers 2024, 16(5), 965; https://doi.org/10.3390/cancers16050965
by Yung-Taek Ouh 1, Yoonji Oh 2, Jinwon Joo 2, Joo Hyun Woo 2, Hye Jin Han 2, Hyun Woong Cho 2, Jae Kwan Lee 2, Yikyeong Chun 3, Myoung-nam Lim 4 and Jin Hwa Hong 2,*
Reviewer 1:
Georgios Iatrakis
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Cancers 2024, 16(5), 965; https://doi.org/10.3390/cancers16050965
Submission received: 2 February 2024 / Revised: 22 February 2024 / Accepted: 23 February 2024 / Published: 27 February 2024
(This article belongs to the Special Issue Endometrial Cancer: Old Questions and New Perspectives (Volume II))

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Considering that cases with POLEmut endometrial cancer have highly favorable outcome (>95% 5-year survival) despite aggressive pathologic features (lymphovascular space invasion and high-grade), please give some hard data explaining this outcome (related to 2020 ESGO...Molecular Categorization System). 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Comments and Suggestions for Authors

The authors have conducted a fascinating study. The abstract and introduction effectively describe the necessity of this research.

However, in the methodology section, it is unclear which classification patients received treatment based on. I assume all patients were treated according to the ESMO 2016 classification, but it would be beneficial if the authors could confirm this.

The results are well-presented, and the discussions are both detailed and concise. Additionally, the references provided are up-to-date and pertinent.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 3 Report

Comments and Suggestions for Authors

This retrospective study evaluated the efficacy of novel molecular classification in EC. In have the following comments:

1. What is the incidence of EC in Korea? This information should be added to the introduction section

2. Why did the authors choose time period between 2012-2021?

3. How many patients are treated for EC each year in the authors' institution and what were the exclusion criteria?

4. In the results section all cases should be reclassified into new 2023 FIGO classification and the results presented in appropriate table.

5. In the discussion section the authors should further discuss rare cases of EC with POLE and p53 mutations present. Is adjuvant therapy indicated in such cases in the early and advanced stages

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop